Citation Impact
Citing Papers
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
2019
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
2018
Head and neck squamous cell carcinoma
2020 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)
2017
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Electronic patient‐reported outcome systems in oncology clinical practice
2012
Pancreatic cancer
2020 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
2009
Targeted treatments in colorectal cancer: state of the art and future perspectives
2010
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Cancer stem cells revisited
2017 Standout
Colorectal cancer
2013 Standout
A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
2017
Delivery technologies for cancer immunotherapy
2019 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Antibody therapy of cancer
2012 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours
2011
The use of combinations of monoclonal antibodies in clinical oncology
2015
Targeting apoptosis in cancer therapy
2020 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Activation of apoptosis signalling pathways by reactive oxygen species
2016 Standout
Gastric cancer
2020 Standout
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy
2009
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
2016
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
2014
Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus
2013
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
2013
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy
2016
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
Marine natural products
2015 Standout
International Anal Neoplasia Society Guidelines for the Practice of Digital Anal Rectal Examination
2019
Chemotherapy for advanced gastric cancer
2017 Standout
Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion
2018
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Advances in Cancer Immunotherapy in Solid Tumors
2016
A Computational Model for Overcoming Drug Resistance Using Selective Dual-Inhibitors for Aurora Kinase A and Its T217D Variant
2013 StandoutNobel
Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
2019
Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
2012
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
2019
Targeting senescent cells in translational medicine
2019
HPV, hypoxia and radiation response in head and neck cancer
2018
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
Works of Hope E. Uronis being referenced
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
2012
Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients
2010
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
2012
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
2014
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results
2009
TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC).
2013
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
2018
NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
2016
A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
2013
A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients
2009
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
2018
Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer
2012
Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)
2009
Anal Cancer: An Overview
2007
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
2014